Literature DB >> 15076220

The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block.

Ruth L Martin1, Jeff S McDermott, Heinz J Salmen, Jason Palmatier, Bryan F Cox, Gary A Gintant.   

Abstract

Drug-induced delayed cardiac repolarization is a recognized risk factor for proarrhythmia and is associated with block of IKr (the potassium current encoded by the human ether-a- go-go-related gene [hERG]). To evaluate the utility of 2 in vitro assays widely used to assess delayed repolarization, we compared the effects of haloperidol and 9 structurally diverse drugs in a hERG and repolarization (canine Purkinje fiber action potential duration [APD]) assay over wide concentrations. Despite potent hERG current block (IC50 = 0.174 microM), haloperidol elicited a bell-shaped concentration-response relationship for APD prolongation, with lesser prolongation (and reduced plateau height) observed with concentrations eliciting maximal hERG block, consistent with multi-channel block at higher concentrations. Consistent with this hypothesis, APD prolongation with the specific IKr blocker dofetilide was a) reduced by concomitant administration of nifedipine (calcium current block) and b) reversed by lidocaine (late sodium current block). Additional studies demonstrated prominent (>50%) hERG inhibition with most (9/10) drugs despite wide APD changes (158% prolongation - 16% shortening), consistent with multi-channel block. The poor correlation between hERG and repolarization assays suggests that the hERG assay oversimplifies drug effects on the complex repolarization process for drugs demonstrating multi-channel block and that neither assay alone adequately predicts proarrhythmic risk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15076220     DOI: 10.1097/00005344-200403000-00007

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  38 in total

1.  In silico assessment of drug safety in human heart applied to late sodium current blockers.

Authors:  Beatriz Trenor; Julio Gomis-Tena; Karen Cardona; Lucia Romero; Sridharan Rajamani; Luiz Belardinelli; Wayne R Giles; Javier Saiz
Journal:  Channels (Austin)       Date:  2013 Jul-Aug       Impact factor: 2.581

Review 2.  Evolution of strategies to improve preclinical cardiac safety testing.

Authors:  Gary Gintant; Philip T Sager; Norman Stockbridge
Journal:  Nat Rev Drug Discov       Date:  2016-02-19       Impact factor: 84.694

Review 3.  An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk.

Authors:  Chris E Pollard; N Abi Gerges; M H Bridgland-Taylor; A Easter; T G Hammond; J-P Valentin
Journal:  Br J Pharmacol       Date:  2010-01       Impact factor: 8.739

4.  Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.

Authors:  L Nalos; R Varkevisser; M K B Jonsson; M J C Houtman; J D Beekman; R van der Nagel; M B Thomsen; G Duker; P Sartipy; T P de Boer; M Peschar; M B Rook; T A B van Veen; M A G van der Heyden; M A Vos
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.

Authors:  Nikunjkumar Patel; Oliver Hatley; Alexander Berg; Klaus Romero; Barbara Wisniowska; Debra Hanna; David Hermann; Sebastian Polak
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

6.  International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.

Authors:  A S Bass; B Darpo; A Breidenbach; K Bruse; H S Feldman; D Garnes; T Hammond; W Haverkamp; C January; J Koerner; C Lawrence; D Leishman; D Roden; J P Valentin; M A Vos; Y-Y Zhou; T Karluss; P Sager
Journal:  Br J Pharmacol       Date:  2008-08       Impact factor: 8.739

7.  Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.

Authors:  L Johannesen; J Vicente; J W Mason; C Erato; C Sanabria; K Waite-Labott; M Hong; J Lin; P Guo; A Mutlib; J Wang; W J Crumb; K Blinova; D Chan; J Stohlman; J Florian; M Ugander; N Stockbridge; D G Strauss
Journal:  Clin Pharmacol Ther       Date:  2015-11-28       Impact factor: 6.875

8.  Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation.

Authors:  Anne S Y Chain; Vincent F S Dubois; Meindert Danhof; Miriam C J M Sturkenboom; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

9.  Electrophysiological profile of propiverine--relationship to cardiac risk.

Authors:  Torsten Christ; Erich Wettwer; Melinda Wuest; Manfred Braeter; Frank Donath; Pascal Champeroux; Serge Richard; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

10.  High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry.

Authors:  Fabio Cerignoli; David Charlot; Ross Whittaker; Randy Ingermanson; Piyush Gehalot; Alex Savchenko; David J Gallacher; Rob Towart; Jeffrey H Price; Patrick M McDonough; Mark Mercola
Journal:  J Pharmacol Toxicol Methods       Date:  2012-08-25       Impact factor: 1.950

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.